Edwards Lifesciences Corporation (EW)
USD 72.81
(-1.77%)
USD 72.81
(-1.77%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.53 Billion USD | -12.26% |
| 2022 | 1.74 Billion USD | 29.66% |
| 2021 | 1.34 Billion USD | -17.19% |
| 2020 | 1.62 Billion USD | 42.0% |
| 2019 | 1.14 Billion USD | 53.27% |
| 2018 | 748.2 Million USD | -26.84% |
| 2017 | 1.02 Billion USD | 30.48% |
| 2016 | 783.8 Million USD | 21.95% |
| 2015 | 642.7 Million USD | 33.17% |
| 2014 | 482.6 Million USD | 6.18% |
| 2013 | 454.5 Million USD | 11.29% |
| 2012 | 408.4 Million USD | 36.09% |
| 2011 | 300.1 Million USD | 5.56% |
| 2010 | 284.3 Million USD | 19.45% |
| 2009 | 238 Million USD | 20.02% |
| 2008 | 198.3 Million USD | 14.89% |
| 2007 | 172.6 Million USD | -0.35% |
| 2006 | 173.2 Million USD | -1.37% |
| 2005 | 175.6 Million USD | 13.73% |
| 2004 | 154.4 Million USD | 11.56% |
| 2003 | 138.4 Million USD | 165.64% |
| 2002 | 52.1 Million USD | 117.08% |
| 2001 | 24 Million USD | -74.74% |
| 2000 | 95 Million USD | -18.8% |
| 1999 | 117 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 437.7 Million USD | 9.4% |
| 2024 Q3 | 394.3 Million USD | 8.12% |
| 2024 Q2 | 364.7 Million USD | -16.68% |
| 2023 Q3 | 418.4 Million USD | 27.87% |
| 2023 Q4 | 400.1 Million USD | -4.37% |
| 2023 FY | 1.53 Billion USD | -12.26% |
| 2023 Q1 | 388.4 Million USD | -13.26% |
| 2023 Q2 | 327.2 Million USD | -15.76% |
| 2022 Q1 | 438.8 Million USD | 17.2% |
| 2022 FY | 1.74 Billion USD | 29.66% |
| 2022 Q3 | 402.4 Million USD | -12.43% |
| 2022 Q2 | 459.5 Million USD | 4.72% |
| 2022 Q4 | 447.8 Million USD | 11.28% |
| 2021 FY | 1.34 Billion USD | -17.19% |
| 2021 Q1 | 383.5 Million USD | 9.13% |
| 2021 Q3 | 390.3 Million USD | -28.0% |
| 2021 Q2 | 542.1 Million USD | 41.36% |
| 2021 Q4 | 374.4 Million USD | -4.07% |
| 2020 Q2 | -169.7 Million USD | -147.39% |
| 2020 Q1 | 358.1 Million USD | 15.22% |
| 2020 Q4 | 351.4 Million USD | -1.79% |
| 2020 Q3 | 357.8 Million USD | 310.84% |
| 2020 FY | 1.62 Billion USD | 42.0% |
| 2019 Q4 | 310.8 Million USD | 5.61% |
| 2019 Q1 | 274.2 Million USD | 5273.58% |
| 2019 Q2 | 267.5 Million USD | -2.44% |
| 2019 Q3 | 294.3 Million USD | 10.02% |
| 2019 FY | 1.14 Billion USD | 53.27% |
| 2018 Q3 | 248.9 Million USD | -1.27% |
| 2018 FY | 748.2 Million USD | -26.84% |
| 2018 Q2 | 252.1 Million USD | -0.16% |
| 2018 Q1 | 252.5 Million USD | 5.25% |
| 2018 Q4 | -5.3 Million USD | -102.13% |
| 2017 Q1 | 309.6 Million USD | 50.29% |
| 2017 FY | 1.02 Billion USD | 30.48% |
| 2017 Q4 | 239.9 Million USD | 8.7% |
| 2017 Q2 | 252.5 Million USD | -18.44% |
| 2017 Q3 | 220.7 Million USD | -12.59% |
| 2016 Q3 | 195.3 Million USD | 8.14% |
| 2016 Q2 | 180.6 Million USD | -10.55% |
| 2016 Q4 | 206 Million USD | 5.48% |
| 2016 Q1 | 201.9 Million USD | 15.57% |
| 2016 FY | 783.8 Million USD | 21.95% |
| 2015 FY | 642.7 Million USD | 33.17% |
| 2015 Q4 | 174.7 Million USD | 12.13% |
| 2015 Q2 | 146.8 Million USD | -11.25% |
| 2015 Q3 | 155.8 Million USD | 6.13% |
| 2015 Q1 | 165.4 Million USD | 17.89% |
| 2014 Q4 | 140.3 Million USD | 8.34% |
| 2014 Q3 | 129.5 Million USD | 8.55% |
| 2014 FY | 482.6 Million USD | 6.18% |
| 2014 Q2 | 119.3 Million USD | 27.59% |
| 2014 Q1 | 93.5 Million USD | -22.98% |
| 2013 Q2 | 122.3 Million USD | 11.69% |
| 2013 FY | 454.5 Million USD | 11.29% |
| 2013 Q4 | 121.4 Million USD | 19.84% |
| 2013 Q3 | 101.3 Million USD | -17.17% |
| 2013 Q1 | 109.5 Million USD | -16.98% |
| 2012 Q2 | 95.8 Million USD | 11.27% |
| 2012 Q1 | 86.1 Million USD | -0.46% |
| 2012 Q3 | 94.6 Million USD | -1.25% |
| 2012 FY | 408.4 Million USD | 36.09% |
| 2012 Q4 | 131.9 Million USD | 39.43% |
| 2011 Q3 | 59.9 Million USD | -20.45% |
| 2011 Q4 | 86.5 Million USD | 44.41% |
| 2011 Q1 | 78.4 Million USD | -2.73% |
| 2011 FY | 300.1 Million USD | 5.56% |
| 2011 Q2 | 75.3 Million USD | -3.95% |
| 2010 Q4 | 80.6 Million USD | 19.58% |
| 2010 FY | 284.3 Million USD | 19.45% |
| 2010 Q1 | 62.7 Million USD | -2.64% |
| 2010 Q2 | 73.6 Million USD | 17.38% |
| 2010 Q3 | 67.4 Million USD | -8.42% |
| 2009 FY | 238 Million USD | 20.02% |
| 2009 Q4 | 64.4 Million USD | 14.18% |
| 2009 Q3 | 56.4 Million USD | -9.76% |
| 2009 Q2 | 62.5 Million USD | 14.26% |
| 2009 Q1 | 54.7 Million USD | -0.36% |
| 2008 Q2 | 52.7 Million USD | 51.87% |
| 2008 FY | 198.3 Million USD | 14.89% |
| 2008 Q4 | 54.9 Million USD | 23.93% |
| 2008 Q3 | 44.3 Million USD | -15.94% |
| 2008 Q1 | 34.7 Million USD | -23.57% |
| 2007 Q2 | 47.1 Million USD | 5.61% |
| 2007 Q3 | 36.6 Million USD | -22.29% |
| 2007 Q1 | 44.6 Million USD | 3.48% |
| 2007 Q4 | 45.4 Million USD | 24.04% |
| 2007 FY | 172.6 Million USD | -0.35% |
| 2006 Q1 | 66 Million USD | 39.83% |
| 2006 Q2 | 45.7 Million USD | -30.76% |
| 2006 FY | 173.2 Million USD | -1.37% |
| 2006 Q3 | 40.2 Million USD | -12.04% |
| 2006 Q4 | 43.1 Million USD | 7.21% |
| 2005 Q4 | 47.2 Million USD | 17.71% |
| 2005 Q1 | 42.6 Million USD | 7.04% |
| 2005 Q2 | 46 Million USD | 7.98% |
| 2005 Q3 | 40.1 Million USD | -12.83% |
| 2005 FY | 175.6 Million USD | 13.73% |
| 2004 Q2 | 40.5 Million USD | 73.08% |
| 2004 FY | 154.4 Million USD | 11.56% |
| 2004 Q4 | 39.8 Million USD | 12.75% |
| 2004 Q3 | 35.3 Million USD | -12.84% |
| 2004 Q1 | 23.4 Million USD | -40.15% |
| 2003 Q4 | 39.1 Million USD | 22.57% |
| 2003 Q1 | 33 Million USD | 6.45% |
| 2003 Q2 | 31.1 Million USD | -5.76% |
| 2003 Q3 | 31.9 Million USD | 2.57% |
| 2003 FY | 138.4 Million USD | 165.64% |
| 2002 FY | 52.1 Million USD | 117.08% |
| 2002 Q2 | 31.1 Million USD | 0.65% |
| 2002 Q4 | 31 Million USD | 175.79% |
| 2002 Q3 | -40.9 Million USD | -231.51% |
| 2002 Q1 | 30.9 Million USD | 14.44% |
| 2001 Q2 | -53.3 Million USD | -297.41% |
| 2001 Q3 | 23.3 Million USD | 143.71% |
| 2001 FY | 24 Million USD | -74.74% |
| 2001 Q4 | 27 Million USD | 15.88% |
| 2001 Q1 | 27 Million USD | -41.3% |
| 2000 FY | 95 Million USD | -18.8% |
| 2000 Q1 | 25 Million USD | 0.0% |
| 2000 Q2 | 8 Million USD | -68.0% |
| 2000 Q3 | 24.3 Million USD | 203.75% |
| 2000 Q4 | 46 Million USD | 89.3% |
| 1999 FY | 117 Million USD | 0.0% |
| 1999 Q4 | 25 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott Laboratories | 6.47 Billion USD | 76.318% |
| Allurion Technologies Inc. | -78.07 Million USD | 2064.83% |
| Artivion, Inc. | 5.74 Million USD | -26617.172% |
| Avanos Medical, Inc. | 4.2 Million USD | -36426.19% |
| Butterfly Network, Inc. | -145.61 Million USD | 1153.568% |
| Butterfly Network, Inc. | -145.61 Million USD | 1153.568% |
| Bio-Rad Laboratories, Inc. | 383.79 Million USD | -299.718% |
| Boston Scientific Corporation | 2.34 Billion USD | 34.524% |
| Perspective Therapeutics, Inc. | -15.18 Million USD | 10204.729% |
| CONMED Corporation | 130.78 Million USD | -1072.985% |
| Paragon 28, Inc. | -37.3 Million USD | 4211.876% |
| Glaukos Corporation | -128.7 Million USD | 1291.997% |
| Globus Medical, Inc. | 133.14 Million USD | -1052.228% |
| Inspire Medical Systems, Inc. | -40.27 Million USD | 3909.441% |
| Integer Holdings Corporation | 167.33 Million USD | -816.811% |
| Medtronic plc | 5.14 Billion USD | 70.177% |
| Nevro Corp. | -99.3 Million USD | 1644.79% |
| Owlet, Inc. | -28.63 Million USD | 5457.991% |
| Penumbra, Inc. | 73.55 Million USD | -1985.764% |
| Vicarious Surgical Inc. | -80.66 Million USD | 2001.793% |
| Smith & Nephew plc | 425 Million USD | -260.965% |
| Sonendo, Inc. | -57.74 Million USD | 2756.772% |
| STERIS plc | 836.11 Million USD | -83.479% |
| Stryker Corporation | 3.88 Billion USD | 60.543% |
| Vapotherm, Inc. | -39.08 Million USD | 4025.537% |
| Zimmer Biomet Holdings, Inc. | 1.27 Billion USD | -20.067% |